Simple Concepts Research Group

3 Biotech Stocks You Should Know About Under $10

by | Oct 28, 2021 | Stock Picks

We Discuss 3 Biotech Stocks Trading At Deep Discounts That You Should Know About

All companies were identified using the Simple Investing Success stock screener, which scans for companies meeting our simple criteria of cheap and good, using simple metrics for discount and valuation.

3 Biotech Stocks You Should Know About

  • Catalyst Pharmaceuticals (CPRX)
  • Surface Oncology (SURF)
  • Voyager Therapeutics (VYGR)

Let’s take a closer look at each company.

catalyst pharma stock cprx cheap bargain

Catalyst Pharmaceuticals (CPRX)

CPRX Stock Rating
  • Earnings Yield: 19.68%
  • 52-week range: $2.87 – $6.59
  • Analyst Price target: $9.12
  • Price/Sales: 5.18
  • Price/Earnings: 8.29

Catalyst Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing therapies for people with rare chronic neuromuscular and neurological diseases. The company has two proprietary drug offerings: Firdapse (used as a form of treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis) and Ruzurgi (used for the treatment of pediatric LEMS patients).

The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis and spinal muscular atrophy. It has license agreements with BioMarin Pharmaceutical and Endo Ventures Limited, for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. The current CEO is Patrick McEnany.

The YTD performance for CPRX is 70.06%.

surface oncology surf stock cheap undervalued

Surface Oncology (SURF)

SURF Stock Rating
  • Earnings Yield: 34.01%
  • 52-week range: $4.95 – $14.40
  • Analyst Price target: $15.91
  • Price/Sales: 2.28
  • Price/Earnings: 21.37

Surface Oncology is a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the US. The company develops various antibodies and an earlier stage program targeting regulatory T cells.Surface also has a strategic collaboration agreement with Novartis Institutes for Biomedical Research for the development of cancer therapies, a license agreement with GlaxoSmithKline to develop and commercialize antibodies and a clinical trial collaboration with Roche Holdings.

Surface Oncology was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The current CEO is Robert Ross, M.D.

The YTD performance for SURF is -20.78%.

voyager therapeutics vygr stock price cheap undervalued

Voyager Therapeutics (VYGR)

VYGR Stock Rating
  • Earnings Yield: 36.29%
  • 52-week range: $2.46 – $12.00
  • Analyst Price target: $8.91
  • Price/Sales: 1.11
  • Price/Earnings: 7.97

Voyager Therapeutics is a clinical-stage gene therapy company that focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead candidate is a treatment for Parkinson’s disease. Voyager also has preclinical programs focusing on the treatment of Huntington’s disease, Alzheimer’s disease and dementia.

Voyager has collaboration agreements with the University of Massachusetts, ClearPoint Neuro, and Thermo Fisher Scientific, to support the development of its gene therapy programs. Additionally, the company has a license agreement with Neurocrine Biosciences for the research, development, and commercialization of gene therapy products.

Voyager Therapeutics was founded in 2013 and is headquartered in Cambridge, Massachusetts. The current CEO is Andre Turenne.

The YTD performance for VYGR is -47.69%.

We hope you enjoyed this list of the Top 3 Biotech stocks under $10. Be sure to add these picks to your Watch List and if you haven’t done so already, check in on the performance of our Current Portfolio. Keep it simple and always do your due diligence.

This material is provided for informational purposes only and is not financial advice. The information contained herein should not solely be used for the formation of an investment decision, whether you are a long term or short term investor.